-
Regorafenib, sold
under the
brand name
Stivarga among others, is an oral multi-kinase
inhibitor developed by
Bayer which targets angiogenic,
stromal and...
-
months compared to 5.6
months for
regorafenib. The
difference in
median PFS
between the
avapritinib and
regorafenib groups was not
statistically significant...
- 2013. "FDA
Approves Regorafenib (Stivarga) for GIST". CancerNetwork.
February 26, 2013.
Retrieved July 29, 2013. "
Regorafenib Prescribing Information"...
-
therapy if RAS wild type, and at
least one of trifluridine/tipiracil or
regorafenib. FRESCO, a multicenter, placebo-controlled
trial conducted in China,...
- dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib,
regorafenib, tofacitinib, and trelagliptin.
BEACON Medicare Limited(BML) is the exclusive...
-
randomized study of
zanzalintinib in
combination with
atezolizumab versus regorafenib in
metastatic colorectal cancer. STELLAR-304 (NCT05678673) is a phase...
-
regadenoson (INN)
regavirumab (INN)
Regenecyte Regitine Reglan Regonol regorafenib (USAN)
regramostim (INN)
regrelor (USAN)
Regroton Regulace Regular Iletin...
- have been
identified for
clinical benefit in GIST: imatinib, sunitinib,
regorafenib,
ripretinib and avapritinib.
Imatinib (Glivec/Gleevec), an
orally administered...
-
Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib Vandetanib WHI-P 154...
-
Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib Vandetanib WHI-P 154...
